These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 15041722)
1. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Foulkes WD; Metcalfe K; Sun P; Hanna WM; Lynch HT; Ghadirian P; Tung N; Olopade OI; Weber BL; McLennan J; Olivotto IA; Bégin LR; Narod SA Clin Cancer Res; 2004 Mar; 10(6):2029-34. PubMed ID: 15041722 [TBL] [Abstract][Full Text] [Related]
2. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers. Krammer J; Pinker-Domenig K; Robson ME; Gönen M; Bernard-Davila B; Morris EA; Mangino DA; Jochelson MS Breast Cancer Res Treat; 2017 Jun; 163(3):565-571. PubMed ID: 28343309 [TBL] [Abstract][Full Text] [Related]
3. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ. Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428 [TBL] [Abstract][Full Text] [Related]
4. Incorporating tumour pathology information into breast cancer risk prediction algorithms. Mavaddat N; Rebbeck TR; Lakhani SR; Easton DF; Antoniou AC Breast Cancer Res; 2010; 12(3):R28. PubMed ID: 20482762 [TBL] [Abstract][Full Text] [Related]
5. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Armes JE; Trute L; White D; Southey MC; Hammet F; Tesoriero A; Hutchins AM; Dite GS; McCredie MR; Giles GG; Hopper JL; Venter DJ Cancer Res; 1999 Apr; 59(8):2011-7. PubMed ID: 10213514 [TBL] [Abstract][Full Text] [Related]
6. Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis. Vaziri SA; Krumroy LM; Elson P; Budd GT; Darlington G; Myles J; Tubbs RR; Casey G Clin Cancer Res; 2001 Jul; 7(7):1937-45. PubMed ID: 11448907 [TBL] [Abstract][Full Text] [Related]
7. Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers. Song Y; Barry WT; Seah DS; Tung NM; Garber JE; Lin NU Cancer; 2020 Jan; 126(2):271-280. PubMed ID: 31581314 [TBL] [Abstract][Full Text] [Related]
9. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A. Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL; Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925 [TBL] [Abstract][Full Text] [Related]
10. Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer. Guzmán-Arocho YD; Rosenberg SM; Garber JE; Vardeh H; Poorvu PD; Ruddy KJ; Kirkner G; Snow C; Tamimi RM; Peppercorn J; Schapira L; Borges VF; Come SE; Brachtel EF; Marotti JD; Warner E; Partridge AH; Collins LC Br J Cancer; 2022 Feb; 126(2):302-309. PubMed ID: 34703009 [TBL] [Abstract][Full Text] [Related]
11. miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers. Vos S; Vesuna F; Raman V; van Diest PJ; van der Groep P Oncotarget; 2015 Oct; 6(31):32115-37. PubMed ID: 26378051 [TBL] [Abstract][Full Text] [Related]
12. Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families. Eerola H; Heinonen M; Heikkilä P; Kilpivaara O; Tamminen A; Aittomäki K; Blomqvist C; Ristimäki A; Nevanlinna H Breast Cancer Res; 2008; 10(1):R17. PubMed ID: 18275599 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer. Sønderstrup IMH; Jensen MB; Ejlertsen B; Eriksen JO; Gerdes AM; Kruse TA; Larsen MJ; Thomassen M; Laenkholm AV Acta Oncol; 2019 Mar; 58(3):363-370. PubMed ID: 30614364 [TBL] [Abstract][Full Text] [Related]
15. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175 [TBL] [Abstract][Full Text] [Related]
16. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Mavaddat N; Barrowdale D; Andrulis IL; Domchek SM; Eccles D; Nevanlinna H; Ramus SJ; Spurdle A; Robson M; Sherman M; Mulligan AM; Couch FJ; Engel C; McGuffog L; Healey S; Sinilnikova OM; Southey MC; Terry MB; Goldgar D; O'Malley F; John EM; Janavicius R; Tihomirova L; Hansen TV; Nielsen FC; Osorio A; Stavropoulou A; Benítez J; Manoukian S; Peissel B; Barile M; Volorio S; Pasini B; Dolcetti R; Putignano AL; Ottini L; Radice P; Hamann U; Rashid MU; Hogervorst FB; Kriege M; van der Luijt RB; ; Peock S; Frost D; Evans DG; Brewer C; Walker L; Rogers MT; Side LE; Houghton C; ; Weaver J; Godwin AK; Schmutzler RK; Wappenschmidt B; Meindl A; Kast K; Arnold N; Niederacher D; Sutter C; Deissler H; Gadzicki D; Preisler-Adams S; Varon-Mateeva R; Schönbuchner I; Gevensleben H; Stoppa-Lyonnet D; Belotti M; Barjhoux L; ; Isaacs C; Peshkin BN; Caldes T; de la Hoya M; Cañadas C; Heikkinen T; Heikkilä P; Aittomäki K; Blanco I; Lazaro C; Brunet J; Agnarsson BA; Arason A; Barkardottir RB; Dumont M; Simard J; Montagna M; Agata S; D'Andrea E; Yan M; Fox S; ; Rebbeck TR; Rubinstein W; Tung N; Garber JE; Wang X; Fredericksen Z; Pankratz VS; Lindor NM; Szabo C; Offit K; Sakr R; Gaudet MM; Singer CF; Tea MK; Rappaport C; Mai PL; Greene MH; Sokolenko A; Imyanitov E; Toland AE; Senter L; Sweet K; Thomassen M; Gerdes AM; Kruse T; Caligo M; Aretini P; Rantala J; von Wachenfeld A; Henriksson K; ; Steele L; Neuhausen SL; Nussbaum R; Beattie M; Odunsi K; Sucheston L; Gayther SA; Nathanson K; Gross J; Walsh C; Karlan B; Chenevix-Trench G; Easton DF; Antoniou AC; Cancer Epidemiol Biomarkers Prev; 2012 Jan; 21(1):134-47. PubMed ID: 22144499 [TBL] [Abstract][Full Text] [Related]
17. Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Couch FJ; Gaudet MM; Antoniou AC; Ramus SJ; Kuchenbaecker KB; Soucy P; Beesley J; Chen X; Wang X; Kirchhoff T; McGuffog L; Barrowdale D; Lee A; Healey S; Sinilnikova OM; Andrulis IL; ; Ozcelik H; Mulligan AM; Thomassen M; Gerdes AM; Jensen UB; Skytte AB; Kruse TA; Caligo MA; von Wachenfeldt A; Barbany-Bustinza G; Loman N; Soller M; Ehrencrona H; Karlsson P; ; Nathanson KL; Rebbeck TR; Domchek SM; Jakubowska A; Lubinski J; Jaworska K; Durda K; Zlowocka E; Huzarski T; Byrski T; Gronwald J; Cybulski C; Górski B; Osorio A; Durán M; Tejada MI; Benitez J; Hamann U; Hogervorst FB; ; van Os TA; van Leeuwen FE; Meijers-Heijboer HE; Wijnen J; Blok MJ; Kets M; Hooning MJ; Oldenburg RA; Ausems MG; Peock S; Frost D; Ellis SD; Platte R; Fineberg E; Evans DG; Jacobs C; Eeles RA; Adlard J; Davidson R; Eccles DM; Cole T; Cook J; Paterson J; Brewer C; Douglas F; Hodgson SV; Morrison PJ; Walker L; Porteous ME; Kennedy MJ; Side LE; ; Bove B; Godwin AK; Stoppa-Lyonnet D; ; Fassy-Colcombet M; Castera L; Cornelis F; Mazoyer S; Léoné M; Boutry-Kryza N; Bressac-de Paillerets B; Caron O; Pujol P; Coupier I; Delnatte C; Akloul L; Lynch HT; Snyder CL; Buys SS; Daly MB; Terry M; Chung WK; John EM; Miron A; Southey MC; Hopper JL; Goldgar DE; Singer CF; Rappaport C; Tea MK; Fink-Retter A; Hansen TV; Nielsen FC; Arason A; Vijai J; Shah S; Sarrel K; Robson ME; Piedmonte M; Phillips K; Basil J; Rubinstein WS; Boggess J; Wakeley K; Ewart-Toland A; Montagna M; Agata S; Imyanitov EN; Isaacs C; Janavicius R; Lazaro C; Blanco I; Feliubadalo L; Brunet J; Gayther SA; Pharoah PP; Odunsi KO; Karlan BY; Walsh CS; Olah E; Teo SH; Ganz PA; Beattie MS; van Rensburg EJ; Dorfling CM; Diez O; Kwong A; Schmutzler RK; Wappenschmidt B; Engel C; Meindl A; Ditsch N; Arnold N; Heidemann S; Niederacher D; Preisler-Adams S; Gadzicki D; Varon-Mateeva R; Deissler H; Gehrig A; Sutter C; Kast K; Fiebig B; Heinritz W; Caldes T; de la Hoya M; Muranen TA; Nevanlinna H; Tischkowitz MD; Spurdle AB; Neuhausen SL; Ding YC; Lindor NM; Fredericksen Z; Pankratz VS; Peterlongo P; Manoukian S; Peissel B; Zaffaroni D; Barile M; Bernard L; Viel A; Giannini G; Varesco L; Radice P; Greene MH; Mai PL; Easton DF; Chenevix-Trench G; ; Offit K; Simard J; Cancer Epidemiol Biomarkers Prev; 2012 Apr; 21(4):645-57. PubMed ID: 22351618 [TBL] [Abstract][Full Text] [Related]
18. Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women. Comen E; Davids M; Kirchhoff T; Hudis C; Offit K; Robson M Breast Cancer Res Treat; 2011 Aug; 129(1):185-90. PubMed ID: 21394499 [TBL] [Abstract][Full Text] [Related]
19. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy. Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786 [TBL] [Abstract][Full Text] [Related]
20. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Karp SE; Tonin PN; Bégin LR; Martinez JJ; Zhang JC; Pollak MN; Foulkes WD Cancer; 1997 Aug; 80(3):435-41. PubMed ID: 9241077 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]